CLAIMS

1. Use of a composition comprising adipose tissue-derived stromal cells (ASCs) in the manufacture of a medicament for treating sepsis in a subject, wherein the sepsis is secondary to an inflammatory lung condition.
2. The use of claim 1, wherein the sepsis is severe sepsis.
3. The use according to any preceding claim, wherein the inflammatory lung condition is pneumonia.
4. The use according to claim 3, wherein the pneumonia is caused by bacteria and/or wherein the pneumonia is community-acquired pneumonia.
5. The use according to any preceding claim, wherein the cells are expanded adipose tissue-derived stromal cells.
6. The use according to any preceding claim, wherein the ASCs are allogeneic.
7. The use according to any preceding claim, wherein the composition comprises between about 0.25×10^6 cells/kg to about 5×10^6 cells/kg of subject weight.
8. The use according to any preceding claim, wherein the ASCs are administered to the subject repeatedly, for example at day 1 and day 3.
9. The use according to any preceding claim, wherein at least about 50% of the ASCs express one or more of the markers CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105.
10. The use according to any preceding claim, wherein at least about 50% of the ASCs do not express the markers Factor VIII, alpha-actin, desmin, S-100, keratin, CD11b, CD11c, CD14, CD45, HLAII, CD31, CD34, CD45, STRO-1 and CD133.
11. The use according to any preceding claim, wherein the ASCs are administered in a pharmaceutically acceptable carrier and/or a diluent.
12. The use according to any preceding claim, wherein the ASCs are administered systemically.
13. The use according to any preceding claim, wherein the ASCs are administered via the subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intralymphatic, intrathecal, intralesional, or intracranial route.
14. The use according to any preceding claim, wherein the ASCs are administered by an intravenous route.
15. The use according to any preceding claim, wherein the ASCs are administered in conjunction with one or more further therapeutic agents.